Document is current
Any future updates will be listed below
-
Authors
Rahbarlayegh, Elnaz
Wojcinski, Alexandre
Nomura, Natsuko
Juarez, Tiffany M.
Blouw, Barbara
Kesari, Santosh https://orcid.org/0000-0003-3772-6000
-
Funding
Funding for this research was provided by:
Fritz B. Burns Foundation (Fritz B. Burns Foundation)
John S. Dunn Research Foundation Center for Radiological Sciences, University of Texas MD Anderson Cancer Center (John S. Dunn Research Foundation Center for Radiological Sciences, University of Texas MD Anderson Cancer Center)
- License Information
-
More Information
Article History
Received: 18 April 2025
Accepted: 29 May 2025
First Online: 10 July 2025
Declarations
:
: Protocol JWCI-17-0401 was approved by the Providence St. Joseph Health (PSJH) Institutional Review Board and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. Informed consent was obtained from the study participant.
: The informed consent provided by the study participant included the consent to publish.
: SK reports research funding to institution from AADi, Aivita Biomedical, Inc., Bavarian Nordic, Bayer, Biocept, Blue Earth Diagnostics, Caris MPI, CNS Pharmaceuticals, EpicentRx, Incyte, Lilly, Oblato, Orbus Therapeutics, and Stemedica Cell Technologies; reports stock or other ownership interests in xCures; reports receiving honoraria from Jubilant Biosys and Pyramid Biosciences; and is a consultant/advisory board member for Curtana Pharmaceuticals, Nascent Biotech, Biocept, iCAD, and xCures. BB is an employee of Plus Therapeutics. All other authors declare no competing interests.
